Dosage forms and methods for oral delivery of progesterone
US6866865B2 · kind B2 · utility
65Cited by
19References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 24, 2003 |
| Grant date | Mar 15, 2005 |
| Priority date | — |
| Expiry date | Feb 24, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/4808
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Oral progesterone unit dosage forms comprising micronized progesterone and a solid polymeric carrier are provided. The dosage forms, upon oral administration, provide a therapeutically effective blood level of progesterone to a subject. The therapeutically effective blood level of progesterone may range from about 0.1 ng/ml to about 400 ng/ml. The dosage forms can be prepared for immediate as well as sustained release. The oral progesterone dosage form can be combined with an estrogen dosage form to provide combination hormone therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.